Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 25, 2005. The report is a disclosure of changes in directors' interests in the company's Ordinary Shares, specifically relating to the GlaxoSmithKline US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on shareholding changes within a specific employee retirement fund.
Material Changes
The primary material change reported is a reduction in the number of Ordinary Share American Depositary Receipts (ADRs) held by the GlaxoSmithKline US Retirement Savings Plan. As of April 21, 2005, the fund's holdings decreased from 18,308,664 to 18,260,668 shares. This movement occurred at an average price of $47.50 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that two directors, Dr. J.P. Garnier and Dr. T. Yamada, are potentially interested in the shares held in the fund in the same manner as other employees or former employees, as the Plan is a discretionary fund for all such personnel.
Investor Verification Points
- Verify the impact of the 47,996 share reduction in the US Retirement Savings Plan on total insider ownership percentages.
- Confirm the average transaction price of $47.50 against market prices on April 21, 2005.
- Review the full 20-F annual report for comprehensive financial performance data, as this 6-K does not contain financial statements.